Market continues its losing streak, Sensex tanks 372 points
Market continues its losing streak, Sensex tanks 372 points

Market continues its losing streak, Sensex tanks 372 points

Nidhi Jani Article rating: 5.0

Meanwhile, foreign investors have taken out the net amount of Rs 3,207 crore from the Country's capital market in the first week of May amid US President's decision to impose tariff on USD 200 billion products imported from China. In addition to this, uncertainty over the election result also weighed on the market sentiments.

Caplin Point gets approval for sterile injectables from Colombia
Caplin Point gets approval for sterile injectables from Colombia

Caplin Point gets approval for sterile injectables from Colombia

Nidhi Jani Article rating: 5.0

The company is hoping that this approval would help to further expand its footprints in Latin America. The company’s Unit 1 is currently catering to emerging markets of Latin America and Africa with a variety of dosage forms such as tablets, capsules, softgel capsules, suppositories, liquid orals and topicals.

Should NRIs buy life insurance in India?
Should NRIs buy life insurance in India?

Should NRIs buy life insurance in India?

DSIJ Intelligence Article rating: 5.0

FEMA (Foreign Exchange Management Act) allows NRIs to buy any type of insurance in India. So, should you as an NRI buy one? Let’s find out.

Pennar group gets orders amounting to Rs 311cr
Pennar group gets orders amounting to Rs 311cr

Pennar group gets orders amounting to Rs 311cr

Nidhi Jani Article rating: 5.0

On Monday, Pennar group informed the bourses that it has received orders worth Rs. 311 crore for the month of April across its various business verticals.


Cadila gets USFDA approval for Chlorthalidone tablets
Cadila gets USFDA approval for Chlorthalidone tablets

Cadila gets USFDA approval for Chlorthalidone tablets

Nidhi Jani Article rating: 5.0

Chlorthalidone tablets are used to treat hypertension. These are also used to reduce extra salt and water in the body caused by conditions such as heart failure, liver disease, and kidney disease.

RSS
First32653266326732683270327232733274Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR